Abstract
The use of tamoxifen for breast cancer therapy is linked to an increased danger of developing endometrial neoplasias in postmenopausal patients receiving the drug. Understanding the molecular mechanisms of the tumorigenic activity of tamoxifen may be of great prognostic and therapeutic significance. Our study suggests that tamoxifen treatment and alterations of the K-ras proto-oncogene may occur as parallel events in carcinogenesis of the endometrium.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.